Quark Releases Positive Phase I Data on Ocular Neuroprotectant
January 12, 2012
Quark Releases Positive Phase I Data on Ocular Neuroprotectant
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Quark to File IND for Eye Disease Rx in September; New Data Shows It May Treat Glaucoma
July 30, 2009 / Gene Silencing News - Quark to Run Phase IIa Trial of RNAi Drug in Glaucoma
May 3, 2012 / Gene Silencing News - Quark Still Sees IPO as a Possibility as Phase II Trials Near Completion
February 9, 2012 / Gene Silencing News - Quark Begins Dosing Second Patient Subgroup in Phase I Study of Ocular Neuroprotection siRNA Drug
October 21, 2010 / Gene Silencing News - Quark Begins Patient Dosing in Phase I Study of Ocular Neuroprotectant
March 4, 2010 / Gene Silencing News